Triple Negative Breast Cancer
Showing NaN - NaN of 43
Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, Endometrial Cancer Trial in Oklahoma City, Houston (AO-252)
Recruiting
- Triple Negative Breast Cancer
- +2 more
-
Oklahoma City, Oklahoma
- +1 more
Nov 13, 2023
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, NSCLC Trial in United States (LYL797)
Recruiting
- Triple Negative Breast Cancer
- +14 more
- LYL797
-
Scottsdale, Arizona
- +10 more
Jan 30, 2023
Triple Negative Breast Cancer, PD-L1 Negative Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Paclitaxel,
Recruiting
- Triple Negative Breast Cancer
- PD-L1 Negative
- Sacituzumab Govitecan-hziy
- +4 more
-
Anchorage, Alaska
- +231 more
Jan 17, 2023
Triple Negative Breast Cancer, PD-L1 Positive Trial in Puerto Rico, United States (Sacituzumab Govitecan-hziy, Pembrolizumab,
Recruiting
- Triple Negative Breast Cancer
- PD-L1 Positive
- Sacituzumab Govitecan-hziy
- +5 more
-
Anchorage, Alaska
- +245 more
Jan 12, 2023
NSCLC, Gastric Carcinoma, Gastroesophageal Junction Carcinoma Trial in Worldwide (SEA-TGT, sasanlimab)
Recruiting
- Non-small Cell Lung Cancer
- +11 more
-
Birmingham, Alabama
- +32 more
Jan 4, 2023
Colorectal Cancer, NSCLC, Triple Negative Breast Cancer Trial in Spain, United Kingdom, United States (GEN1029
Terminated
- Colorectal Cancer
- +6 more
- GEN1029 (HexaBody®-DR5/DR5)
-
New Haven, Connecticut
- +5 more
Nov 11, 2022
Squamous Cell Carcinoma of Head and Neck, NSCLC, Hepatocellular Carcinoma Trial in Worldwide (KY1044, KY1044 and atezolizumab)
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- +11 more
- KY1044
- KY1044 and atezolizumab
-
New Haven, Connecticut
- +12 more
Nov 3, 2022
Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial in United States (Paclitaxel, CB-839)
Completed
- Triple Negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer
-
Birmingham, Alabama
- +24 more
Sep 19, 2022
Advanced Solid Tumor, Metastatic Cancer, Refractory Cancer Trial in Huntersville, Houston, Webster (PT199, Anti-PD-1 mAb)
Recruiting
- Advanced Solid Tumor
- +18 more
- PT199
- Anti-PD-1 monoclonal antibody
-
Huntersville, North Carolina
- +2 more
Aug 10, 2022
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone Trial in Houston (biological, drug, other)
Recruiting
- Bone Sarcoma
- +15 more
- Aldesleukin
- +8 more
-
Houston, TexasM D Anderson Cancer Center
Aug 3, 2022
Triple Negative Breast Cancer Trial in Canada, United States (Placebo, Atezolizumab)
Active, not recruiting
- Triple Negative Breast Cancer
- Placebo
- Atezolizumab
-
Mobile, Alabama
- +216 more
Jul 27, 2022
NSCLC, Ovarian Cancer, Fallopian Tube Cancer Trial in United States (CART-TnMUC1, Cyclophosphamide, Fludarabine)
Active, not recruiting
- Non-Small Cell Lung Cancer
- +5 more
- CART-TnMUC1
- +2 more
-
Phoenix, Arizona
- +9 more
Jul 18, 2022
Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer Trial in United States (NT-I7,
Recruiting
- Any Advanced Solid Tumors
- +6 more
-
Tampa, Florida
- +7 more
Jul 13, 2022
Ovarian Cancer, Bladder Cancer, Non Small Cell Lung Cancer Trial in Worldwide (INCB106385, INCMGA00012)
Recruiting
- Ovarian Cancer
- +10 more
-
West Hollywood, California
- +27 more
Jun 27, 2022
Hormone Receptor Positive Breast Cancer, Triple Negative Breast Cancer, NSCLC Trial in Japan, United States (Datopotamab
Recruiting
- Hormone Receptor Positive Breast Cancer
- +2 more
- Datopotamab Deruxtecan (Dato-DXd)
-
Los Angeles, California
- +13 more
Jun 21, 2022
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (Combination of NKTR-214 + nivolumab)
Completed
- Melanoma
- +6 more
- Combination of NKTR-214 + nivolumab
-
La Jolla, California
- +57 more
Jun 22, 2022
Triple Negative Breast Cancer, Anthracycline-refractory TNBC Trial in Houston (Docetaxel, Pembrolizumab, IL-12 gene therapy)
Suspended
- Triple Negative Breast Cancer
- Anthracycline-refractory TNBC
- Docetaxel
- +2 more
-
Houston, TexasHouston Methodist Cancer Center
Mar 28, 2022
Triple Negative Breast Cancer Trial in United States (Cisplatin, Paclitaxel)
Active, not recruiting
- Triple Negative Breast Cancer
-
Birmingham, Alabama
- +19 more
Feb 14, 2022